Moderna stock jumps 177% on first positive Phase 3 for a personalized cancer vaccine

Markets/Moderna/
Moderna stock jumps 177% on first positive Phase 3 for a personalized cancer vaccine
Illustration

Moderna and Merck said their individualized mRNA therapy intismeran, paired with Keytruda, met its primary endpoint in a Phase 3 melanoma trial, the first positive Phase 3 for any mRNA cancer therapy. Moderna shares closed at $174.38 on Wednesday, up 177% on the day. The companies gave topline results only, withholding effect sizes, and overall survival data are not yet mature.

3 sources

  1. 01CNBC — Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soarcnbc.com
  2. 02Fortune — Moderna and Merck personalized mRNA vaccine shows real promise against melanoma in late-stage trialfortune.com
  3. 03Business Wire — Merck and Moderna Announce Phase 3 INTerpath-001 Trial Met Endpoints of RFS and DMFSbusinesswire.com